PDCD1 and hepatocellular carcinoma: And in the TISIDB database, we also found that PARP2 is negatively correlated with the immunosuppressive factor PD-L1, so we hypothesize that PARP inhibitors combined with PD1 monoclonal antibody can enhance the effect of treating HCC.